3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
65
Phase 3
56
Phase 1
36
Phase 1/2
22
Phase 4
2
Phase 2/3
2
Status
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
4
INDUSTRY
2
NETWORK
1
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Multiple Myeloma
2
Interventions
Cisplatin
29
Carboplatin
28
Gemcitabine
27
Paclitaxel
26
pembrolizumab
24
Capecitabine
16
Pemetrexed
15
Bevacizumab
15
Docetaxel
14
Oxaliplatin
13
Fluorouracil
12
Drug Therapy
12
Nivolumab
10
130-nm albumin-bound paclitaxel
9
Trastuzumab
8
anlotinib
7
Injections
7
Rituximab
6
venetoclax
5
atezolizumab
5
Temozolomide
5
Leucovorin
5
Ipilimumab
5
Lenalidomide
4
Irinotecan
4
Interferon alpha-2
4
Folfox protocol
4
Dexamethasone
4
Azacitidine
4
Albumin-Bound Paclitaxel
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
INDUSTRY
×
Bortezomib
×
Clear all
NCT07428369
2026-02-23
LINKER-MM8
Regeneron Pharmaceuticals
Phase 2/3
Not yet recruiting
1,570 enrolled
NCT00514371
2015-12-07
TIME-2
Bristol-Myers Squibb
Phase 2/3
Completed
22 enrolled